Clinical pharmacokinetics of sotalol

James Hanyok(Daiichi Sankyo (United States))

The American Journal of Cardiology

August 1, 1993

10.1016/0002-9149(93)90021-4

Cited by 72

Related Papers

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

|New England Journal of Medicine|2013|5.2k

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

|American Heart Journal|2010|482

Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis

|New England Journal of Medicine|2006|397

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|390

Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study

|American Heart Journal|1995|121